ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

EVGN Evogene Ltd

2.88
0.07 (2.49%)
14 Sep 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Evogene Ltd NASDAQ:EVGN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.07 2.49% 2.88 2.76 3.07 2.955 2.80 2.83 10,583 01:00:00

Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

12/08/2024 12:11pm

PR Newswire (US)


Evogene (NASDAQ:EVGN)
Historical Stock Chart


From Jul 2024 to Sep 2024

Click Here for more Evogene Charts.

REHOVOT, Israel, Aug. 12, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) (the "Company", "Evogene"), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, today reported the receipt of a formal notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Listing Rule 5550(a)(2), which requires the Company's ordinary shares to maintain a minimum bid price of $1.00 per share.

Evogene_Logo

The Nasdaq staff made this determination of compliance after the closing bid price of the Company's ordinary shares was at $1.00 per share or greater for the prior 10 consecutive business days. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and Nasdaq considers the prior bid price deficiency matter now closed.

About Evogene Ltd.:

Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science-based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost.

Evogene established three unique tech-engines - MicroBoost AIChemPass AI and GeneRator AI. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).

Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its five subsidiaries including:

  1. Biomica Ltd. (www.biomicamed.com) developing and advancing novel microbiome-based therapeutics to treat human disorders powered by MicroBoost AI;
  2. Lavie Bio Ltd. (www.lavie-bio.com) - developing and commercially advancing, microbiome based ag-biologicals powered by MicroBoost AI;
  3. AgPlenus Ltd. (www.agplenus.com) -developing next generation ag chemicals for effective and sustainable crop protection powered by ChemPass AI;
  4. Casterra Ag Ltd. (www.casterra.co)– developing and marketing superior castor seed varieties producing high yield and high-grade oil content, on an industrial scale for the biofuel and other industries powered by GeneRator AI.

For more information, please visit: www.evogene.com.

Evogene Investor Contact


Rachel Pomerantz Gerber

Head of Investor Relations at Evogene

rachel.pomerantz@evogene.com 

Tel: +972-8-9311901


Cision View original content:https://www.prnewswire.com/news-releases/evogene-regains-compliance-with-nasdaq-minimum-closing-bid-price-rule-302219815.html

SOURCE Evogene

Copyright 2024 PR Newswire

1 Year Evogene Chart

1 Year Evogene Chart

1 Month Evogene Chart

1 Month Evogene Chart

Your Recent History

Delayed Upgrade Clock